Cytomegalovirus (CMV) infections in renal transplant recipients. Preliminary results of prophylaxis by an intramuscular human hyperimmune CMV IgG.
Infectious diseases are the most serious complications in immunosuppressed patients and the major cause of death in renal transplant recipients (23, 44). Besides bacterial, fungal and protozoan infections, viruses of the human herpes group (herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus) are known to be of major importance (21, 37). The most common and clinically relevant virus of this group is the cytomegalovirus (CMV).
D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003168:Complement Fixation Tests; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000276:immunology / Q000517:prevention & control*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D007273:Injections, Intramuscular; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011446:Prospective Studies
D000914:Antibodies, Viral; D007074:Immunoglobulin G